Home Biosimilar Antibodies Immunology & Inflammation CD markers Lacutamab (Anti-KIR3DL2 / CD158k)
For research use only. Not for use in humans.

Lacutamab (Anti-KIR3DL2 / CD158k)

Synonyms: IPH 4102

Lacutamab (Anti-KIR3DL2 / CD158k) is a humanized monoclonal antibody against the immune receptor human killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), with potential immunomodulating and antineoplastic activities. MW: 150 kD.

Lacutamab (Anti-KIR3DL2 / CD158k)

Quality Control

Batch: Purity: 99% Protein concentration: 6.394mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Lacutamab (Anti-KIR3DL2 / CD158k) is a humanized monoclonal antibody against the immune receptor human killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), with potential immunomodulating and antineoplastic activities. MW: 150 kD.

Product Details

CAS No.  2187368-16-5
Molecular Weight 150 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04984837 ACTIVE_NOT_RECRUITING Drug: Lacutamab|Drug: Gemcitabine|Drug: Oxaliplatine Peripheral T Cell Lymphoma; Relapse/Recurrence The Lymphoma Academic Research Organisation 2021-10-05 PHASE2
NCT03902184 COMPLETED Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides/Sezary Syndrome Innate Pharma 2019-05-22 PHASE2
NCT05321147 COMPLETED Peripheral T Cell Lymphoma Innate Pharma 2022-03-17 PHASE1
NCT02593045 COMPLETED Cutaneous T-Cell Lymphoma Innate Pharma 2015-10 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-06-04)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.